<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734604</url>
  </required_header>
  <id_info>
    <org_study_id>12313</org_study_id>
    <secondary_id>H6D-CR-S024</secondary_id>
    <nct_id>NCT00734604</nct_id>
  </id_info>
  <brief_title>A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.</brief_title>
  <official_title>A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to help answer whether tadalafil taken once a day can
      help improve the psychological outcomes (such as sexual self confidence, spontaneity and time
      concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint</measure>
    <time_frame>8 weeks of each treatment</time_frame>
    <description>EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Serious Adverse Event</measure>
    <time_frame>baseline through 26 weeks (including two washout periods of 1 week each)</time_frame>
    <description>Serious adverse events are listed in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score</measure>
    <time_frame>baseline, 8 weeks of each treatment</time_frame>
    <description>Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question 1 &quot;I Felt as if I Did Not Have ED&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</measure>
    <time_frame>8 weeks of each treatment</time_frame>
    <description>Scores for Question 1 range from 0 (not at all) to 4 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question 2 &quot;I Felt in Control of my Sex Life&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</measure>
    <time_frame>8 weeks of each treatment</time_frame>
    <description>Scores for Question 2 range from 0 (not at all) to 4 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question 3 &quot;I Felt the Drug Was in Control of my Erections&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</measure>
    <time_frame>8 weeks of each treatment</time_frame>
    <description>Scores for Question 3 range from 0 (not at all) to 4 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question 4 &quot;I Felt Like a Whole Man&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</measure>
    <time_frame>8 weeks of each treatment</time_frame>
    <description>Scores for Question 4 range from 0 (not at all) to 4 (extremely).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>T(OaD)/S(PRN)/T(PRN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T(OaD)/T(PRN)/S(PRN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S(PRN)/T(OaD)/T(PRN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S(PRN)/T(PRN)/T(OaD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T(PRN)/T(OaD)/S(PRN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T(PRN)/S(PRN)/T(OaD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil once a day [T(OaD)]</intervention_name>
    <description>5 mg tablet taken once a day (OaD) by mouth for 8 weeks</description>
    <arm_group_label>T(OaD)/S(PRN)/T(PRN)</arm_group_label>
    <arm_group_label>T(OaD)/T(PRN)/S(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(OaD)/T(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(PRN)/T(OaD)</arm_group_label>
    <arm_group_label>T(PRN)/T(OaD)/S(PRN)</arm_group_label>
    <arm_group_label>T(PRN)/S(PRN)/T(OaD)</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>LY450190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate as needed [S(PRN)]</intervention_name>
    <description>100 mg tablet taken as needed (PRN) by mouth for 8 weeks</description>
    <arm_group_label>T(OaD)/S(PRN)/T(PRN)</arm_group_label>
    <arm_group_label>T(OaD)/T(PRN)/S(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(OaD)/T(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(PRN)/T(OaD)</arm_group_label>
    <arm_group_label>T(PRN)/T(OaD)/S(PRN)</arm_group_label>
    <arm_group_label>T(PRN)/S(PRN)/T(OaD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil as needed [T(PRN)]</intervention_name>
    <description>20 mg tablet taken as needed (PRN) by mouth for 8 weeks</description>
    <arm_group_label>T(OaD)/S(PRN)/T(PRN)</arm_group_label>
    <arm_group_label>T(OaD)/T(PRN)/S(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(OaD)/T(PRN)</arm_group_label>
    <arm_group_label>S(PRN)/T(PRN)/T(OaD)</arm_group_label>
    <arm_group_label>T(PRN)/T(OaD)/S(PRN)</arm_group_label>
    <arm_group_label>T(PRN)/S(PRN)/T(OaD)</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>LY450190</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of erectile dysfunction (ED).

          -  Have had satisfactory response to tadalafil, sildenafil citrate, or vardenafil HCl for
             a period of at least 6 months and expect frequent use (at least one dose per week, on
             average) when administered as needed.

          -  Have never used tadalafil 5 mg or 2.5 mg once a day therapy.

          -  Anticipate having the same adult female sexual partner willing to participate during
             the study.

          -  Agree to make at least four sexual intercourse attempts during the first four weeks of
             the study.

          -  Agree not to use any other treatment for ED (even herbal treatments) during the study.

          -  Agree to follow the directions given by the study doctor and staff about using the
             study drug.

        Exclusion Criteria:

          -  Have any other primary sexual disorders present or penile deformity.

          -  Have history of radical prostatectomy or penile implant.

          -  Have problems with your kidneys, liver, or nervous system.

          -  Have uncontrolled diabetes, as measured by a blood test for haemoglobin A1C greater
             than a value of 11%.

          -  Are being treated for heart disease with any drug that is called a nitrate (for
             example, nitroglycerin).

          -  Have chest pain (called unstable angina or angina) that requires treatment.

          -  Have heart disease that causes symptoms after you exert yourself.

          -  Have had any of the following in the past 90 days: Heart attack, also known as a
             myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft
             surgery); Had a procedure to open up blood vessels in the heart known as angioplasty
             or stent placement (percutaneous coronary intervention).

          -  Have a history of loss of vision in one eye because of nonarteritic anterior ischemic
             optic neuropathy (NAION).

          -  Have retinitis pigmentosa.

          -  Have history of human immunodeficiency virus (HIV).

          -  Have very high or very low blood pressure (your study doctor will discuss the limits
             with you).

          -  Have had a stroke or a significant injury to your brain or spinal cord within the last
             6 months.

          -  Have rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption Lactose intolerance.

          -  Have a scheduled or planned surgery requiring anaesthesia during the course of the
             study.

          -  Have a scheduled cataract surgery during the curse of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Easter Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goiânia</city>
        <zip>74110-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio Claro</city>
        <zip>13500-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20725-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sao Jose Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04044-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Joya</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santurce</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malaga</city>
        <zip>29007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durham</city>
        <state>County Durham</state>
        <zip>DH1 2QW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plymouth</city>
        <state>Devonshire</state>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lichfield</city>
        <state>Staffordshire</state>
        <zip>WS14 9JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>NW8 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>September 20, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2010</results_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T(OaD)/S(PRN)/T(PRN)</title>
          <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>T(OaD)/T(PRN)/S(PRN)</title>
          <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>S(PRN)/T(OaD)/T(PRN)</title>
          <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>S(PRN)/T(PRN)/T(OaD)</title>
          <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
        </group>
        <group group_id="P5">
          <title>T(PRN)/T(OaD)/S(PRN)</title>
          <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
        </group>
        <group group_id="P6">
          <title>T(PRN)/S(PRN)/T(OaD)</title>
          <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="63"/>
                <participants group_id="P6" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T(OaD)/S(PRN)/T(PRN)</title>
          <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>T(OaD)/T(PRN)/S(PRN)</title>
          <description>Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>S(PRN)/T(OaD)/T(PRN)</title>
          <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>S(PRN)/T(PRN)/T(OaD)</title>
          <description>Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>T(PRN)/T(OaD)/S(PRN)</title>
          <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks</description>
        </group>
        <group group_id="B6">
          <title>T(PRN)/S(PRN)/T(OaD)</title>
          <description>Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="63"/>
            <count group_id="B6" value="64"/>
            <count group_id="B7" value="378"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.53" spread="11.62"/>
                    <measurement group_id="B2" value="55.12" spread="8.89"/>
                    <measurement group_id="B3" value="55.40" spread="11.70"/>
                    <measurement group_id="B4" value="54.87" spread="12.04"/>
                    <measurement group_id="B5" value="59.04" spread="10.56"/>
                    <measurement group_id="B6" value="54.36" spread="10.28"/>
                    <measurement group_id="B7" value="56.21" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.35" spread="4.18"/>
                    <measurement group_id="B2" value="27.62" spread="2.65"/>
                    <measurement group_id="B3" value="27.77" spread="3.71"/>
                    <measurement group_id="B4" value="28.68" spread="4.74"/>
                    <measurement group_id="B5" value="27.80" spread="3.51"/>
                    <measurement group_id="B6" value="29.08" spread="4.26"/>
                    <measurement group_id="B7" value="28.22" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erectile Dysfunction (ED) Duration</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>=&gt; 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="59"/>
                    <measurement group_id="B7" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt; than 6 months through &lt;1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ED Etiology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychogenic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior sildenafil citrate use as needed (PRN)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Vardenafil HCl use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</title>
        <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</title>
          <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.62"/>
                    <measurement group_id="O2" value="2.23" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.78" lower_limit="0.41" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.39" spread="0.67" lower_limit="0.29" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>p-value is for difference in LS Means change from baseline between tadalafil OaD and Sildenafil PRN.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</title>
        <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)</title>
          <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.62"/>
                    <measurement group_id="O2" value="2.24" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.78"/>
                    <measurement group_id="O2" value="0.50" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.872</p_value>
            <p_value_desc>p-value is for difference in Pairs Sexual Self-Confidence Domain Score LS Mean and Change from Baseline between Tadalafil OaD and Tadalafil PRN Population</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>LS Mean difference = Tadalafil OaD-Tadalafil PRN</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS</title>
        <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS</title>
          <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.48"/>
                    <measurement group_id="O2" value="3.07" spread="0.48"/>
                    <measurement group_id="O3" value="3.07" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.50"/>
                    <measurement group_id="O2" value="-0.05" spread="0.49"/>
                    <measurement group_id="O3" value="0.07" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Sildenafil PRN change from baseline in LS Mean.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.395</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Tadalafil PRN in change from baseline in LS Mean.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS</title>
        <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS</title>
          <description>The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.53"/>
                    <measurement group_id="O2" value="2.42" spread="0.54"/>
                    <measurement group_id="O3" value="2.42" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.53"/>
                    <measurement group_id="O3" value="-0.17" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN in Change from Baseline in LS Mean.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN in Change from Baseline in LS Mean.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)</title>
        <description>Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)</title>
          <description>Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.60" spread="6.26"/>
                    <measurement group_id="O2" value="15.40" spread="6.27"/>
                    <measurement group_id="O3" value="15.55" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.68" spread="6.94"/>
                    <measurement group_id="O2" value="9.70" spread="7.01"/>
                    <measurement group_id="O3" value="9.54" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection</title>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection</title>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.26"/>
                    <measurement group_id="O2" value="0.28" spread="0.26"/>
                    <measurement group_id="O3" value="0.27" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.29"/>
                    <measurement group_id="O2" value="0.20" spread="0.25"/>
                    <measurement group_id="O3" value="0.11" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF</title>
        <description>Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF</title>
          <description>Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="2.76"/>
                    <measurement group_id="O2" value="8.34" spread="2.77"/>
                    <measurement group_id="O3" value="8.37" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="3.16"/>
                    <measurement group_id="O2" value="3.99" spread="3.17"/>
                    <measurement group_id="O3" value="3.83" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF</title>
        <description>Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF</title>
          <description>Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="2.34"/>
                    <measurement group_id="O2" value="5.22" spread="2.36"/>
                    <measurement group_id="O3" value="5.27" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="2.61"/>
                    <measurement group_id="O2" value="2.87" spread="2.55"/>
                    <measurement group_id="O3" value="2.84" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint</title>
        <description>EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).</description>
        <time_frame>8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint</title>
          <description>EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.81" spread="22.36"/>
                    <measurement group_id="O2" value="75.68" spread="19.58"/>
                    <measurement group_id="O3" value="79.50" spread="19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil PRN and Sildenafil PRN change in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>6.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN change in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.05</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Serious Adverse Event</title>
        <description>Serious adverse events are listed in the Reported Adverse Event module.</description>
        <time_frame>baseline through 26 weeks (including two washout periods of 1 week each)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Serious Adverse Event</title>
          <description>Serious adverse events are listed in the Reported Adverse Event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score</title>
        <description>Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1–8) and Confidence (items 9–14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.</description>
        <time_frame>baseline, 8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score</title>
          <description>Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1–8) and Confidence (items 9–14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.28" spread="21.36"/>
                    <measurement group_id="O2" value="50.50" spread="21.58"/>
                    <measurement group_id="O3" value="50.69" spread="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.94" spread="24.86"/>
                    <measurement group_id="O2" value="22.87" spread="24.43"/>
                    <measurement group_id="O3" value="24.13" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.</p_value_desc>
            <method>t-test</method>
            <method_desc>Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.35</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Question 1 &quot;I Felt as if I Did Not Have ED&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
        <description>Scores for Question 1 range from 0 (not at all) to 4 (extremely).</description>
        <time_frame>8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Question 1 &quot;I Felt as if I Did Not Have ED&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
          <description>Scores for Question 1 range from 0 (not at all) to 4 (extremely).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.25"/>
                    <measurement group_id="O2" value="1.78" spread="1.13"/>
                    <measurement group_id="O3" value="1.77" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.367</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Question 2 &quot;I Felt in Control of my Sex Life&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
        <description>Scores for Question 2 range from 0 (not at all) to 4 (extremely).</description>
        <time_frame>8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Question 2 &quot;I Felt in Control of my Sex Life&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
          <description>Scores for Question 2 range from 0 (not at all) to 4 (extremely).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.09"/>
                    <measurement group_id="O2" value="2.14" spread="1.01"/>
                    <measurement group_id="O3" value="2.36" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.722</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Question 3 &quot;I Felt the Drug Was in Control of my Erections&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
        <description>Scores for Question 3 range from 0 (not at all) to 4 (extremely).</description>
        <time_frame>8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Question 3 &quot;I Felt the Drug Was in Control of my Erections&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
          <description>Scores for Question 3 range from 0 (not at all) to 4 (extremely).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="1.19"/>
                    <measurement group_id="O2" value="2.28" spread="1.12"/>
                    <measurement group_id="O3" value="2.50" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Question 4 &quot;I Felt Like a Whole Man&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
        <description>Scores for Question 4 range from 0 (not at all) to 4 (extremely).</description>
        <time_frame>8 weeks of each treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Once a Day [T(OaD)]</title>
            <description>Tadalafil 5 mg once a day [T(OaD)]</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil as Needed [S(PRN)]</title>
            <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil as Needed [T(PRN)]</title>
            <description>Tadalafil 20 mg as needed [T(PRN)]</description>
          </group>
        </group_list>
        <measure>
          <title>Question 4 &quot;I Felt Like a Whole Man&quot; Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint</title>
          <description>Scores for Question 4 range from 0 (not at all) to 4 (extremely).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="1.10"/>
                    <measurement group_id="O2" value="2.57" spread="1.06"/>
                    <measurement group_id="O3" value="2.44" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <p_value_desc>p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil Once a Day [T(OaD)]</title>
          <description>Tadalafil 5 mg once a day [T(OaD)]</description>
        </group>
        <group group_id="E2">
          <title>Sildenafil Citrate as Needed [S(PRN)]</title>
          <description>Sildenafil citrate 100 mg as needed [S(PRN)]</description>
        </group>
        <group group_id="E3">
          <title>Tadalafil as Needed [T(PRN)]</title>
          <description>Tadalafil 20 mg as needed [T(PRN)]</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elbow operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cyanopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Metamorphopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Visual brightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="10" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="378"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="10" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="19" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="378"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="378"/>
                <counts group_id="E3" events="18" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ejaculation failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="378"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="378"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" events="26" subjects_affected="8" subjects_at_risk="378"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

